Naples Global Advisors LLC Sells 786 Shares of Abbott Laboratories $ABT

Naples Global Advisors LLC lowered its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 28,284 shares of the healthcare product maker’s stock after selling 786 shares during the period. Naples Global Advisors LLC’s holdings in Abbott Laboratories were worth $3,847,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Pure Financial Advisors LLC boosted its stake in Abbott Laboratories by 162.4% during the second quarter. Pure Financial Advisors LLC now owns 23,306 shares of the healthcare product maker’s stock worth $3,170,000 after acquiring an additional 14,423 shares in the last quarter. Woodward Diversified Capital LLC boosted its stake in Abbott Laboratories by 30.5% during the second quarter. Woodward Diversified Capital LLC now owns 6,056 shares of the healthcare product maker’s stock worth $824,000 after acquiring an additional 1,417 shares in the last quarter. Community Financial Services Group LLC boosted its stake in Abbott Laboratories by 874.7% during the second quarter. Community Financial Services Group LLC now owns 45,110 shares of the healthcare product maker’s stock worth $6,135,000 after acquiring an additional 40,482 shares in the last quarter. Madrona Financial Services LLC boosted its stake in Abbott Laboratories by 9.7% during the second quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker’s stock worth $235,000 after acquiring an additional 152 shares in the last quarter. Finally, SOA Wealth Advisors LLC. boosted its stake in Abbott Laboratories by 142.5% during the second quarter. SOA Wealth Advisors LLC. now owns 1,113 shares of the healthcare product maker’s stock worth $151,000 after acquiring an additional 654 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $133.53 on Thursday. The company has a 50 day moving average price of $131.63 and a 200-day moving average price of $131.24. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The firm has a market capitalization of $232.39 billion, a PE ratio of 16.73, a P/E/G ratio of 2.54 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the business posted $1.14 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ABT shares. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Royal Bank Of Canada lifted their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Tuesday, July 15th. Evercore ISI lifted their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Finally, Leerink Partners started coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $145.39.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.